Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study

Kidney International, Supplement

Volumn 66, Issue 90, 2004, Pages

  Qunibi, Wajeh Y ^a   Nolan, Charles R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Calcium; Calcium acetate; Calcium phosphorus product; Chronic kidney disease; Hyperphosphatemia; Phosphate binder; Sevelamer hydrochloride

Indexed keywords

CALCIUM; CALCIUM ACETATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; ACETIC ACID DERIVATIVE; PHOSPHORUS;

CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; MORTALITY; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; DOUBLE BLIND PROCEDURE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ACETATES; CALCIUM; DOUBLE-BLIND METHOD; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS;

EID: 4344605167     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09006.x     Document Type: Review

References (23)

1. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
2. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S201, 2003
3. RUFINO M, DE BONIS E, MARTIN M, et al: Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transpl 13:65-67, 1998
4. NOLAN CR, QUNIBI WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Current Opinion Nephrol Hypertens 12:373-79, 2003
5. MUSCI I, HERCZ G, ULDALL R, et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998
6. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
7. BLEYER AJ, BURKE SK, DILLON M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
8. SLATOPOLSKY EA, BURKE SK, DILLON MA, et al: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299-307, 1999
9. GOLDBERG DI, DILLON MA, SLATOPOLSKY EA, et al: Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13:2303-2310, 1998
10. CHERTOW GM, BURKE SK, RAGGI P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
11. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-26, 2004
12. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease. J Am Coll Cardiol 39:695-701, 2002
13. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
14. FOLEY RN, PARFREY PS, HARNETT JD, et al: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16:386-393, 1996
15. CHERTOW GM, DILLON GM, BURKE SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999
16. SHEIKH MS, SANTA ANA CA, NICAR MJ, et al: Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 317:532-536, 1987
17. SHEIKH MS, MAGUIRE JA, EMMETT M, et al: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 83:66-73, 1989
18. MCINTYRE CW, PATEL V, TAYLOR GS, et al: A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcemic haemodialysis patients. Nephrol Dial Transplant 17:1643-1648, 2002
19. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
20. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
21. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
22. QUNIBI WY, NOLAN CR, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int 62(Suppl 82):S73-S80, 2002
23. Drug Topics Red Book: Montvale, NJ, Thomson PDR, 2003